Specialists at the IMO AGM discussed the rise of semaglutide as a weight-loss drug, with newer, more effective medications on the horizon. Prof Donal O’Shea highlighted the potential of tirzepatide and retatrutide in treating obesity. He emphasized the need for a shift in how obesity is treated, debunking the “eat less, move more” myth. The toxic environment of marketing high-fat, high-sugar foods was blamed for the doubling of obesity rates in the population. Dr Mary T O’Mahony addressed the impact of alcohol consumption, particularly on newborns with foetal alcohol spectrum disorder. She criticized Government proposals to increase trading hours in bars and called for measures to reduce alcohol affordability.
Source link
New obesity medicines to be ‘way more effective’ than Ozempic
